Genitope Corporation's MyVax(R) Personalized Immunotherapy Pivotal Phase 3 Trial Results Available on Company Website
Published: Apr 09, 2008
FREMONT, Calif.--(BUSINESS WIRE)--Genitope Corporation (Genitope, NASDAQ: GTOP) today announced that a summary of the data from its pivotal Phase 3 clinical trial examining the use of MyVax® personalized immunotherapy (MyVax) in previously untreated follicular B-cell non-Hodgkin’s lymphoma (fNHL) patients is available on the Investor Relations section of Genitope’s Web site at http://ir.genitope.com. In December 2007, Genitope obtained data indicating that its pivotal Phase 3 clinical trial did not meet its primary endpoint. The primary analysis demonstrated that there was no statistically significant difference in the progression-free survival (PFS) of patients receiving MyVax compared to patients receiving a non-specific control immunotherapy. However, analysis of a pre-specified endpoint in the group of patients receiving MyVax showed a highly statistically significant difference in PFS between patients who mounted a positive immune response to the tumor-specific target and those who did not.